

Neuroscience Grand Rounds 2025

Neuroscience Grand Rounds 2025 - 1/31/2025 Redefining Neurodegeneration: Beyond the Century-Old Clinicopathologic Model

January 31, 2025 – 8:00 AM
Other

Overall Activity Objectives:

- 1 Incorporate into practice current evidence-based practices to get patients with stroke the most appropriate treatment/intervention in the shortest time possible.
- 2 Incorporate disease modifying therapies into the treatment plan for individuals with multiple sclerosis based on the most current clinical research and professional society guidelines and the underlying science regarding mechanism of action.
- 3 Evaluate patients with neuromuscular disease for the use of the latest treatments, based on evidence-based guidelines and publications.
- 4 Treat patients with migraine with the latest agents and strategies when traditional treatments fail.
- 5 Refer patients with Parkinson's disease and other movement disorders for neuromodulatory treatments sooner in their treatment paradigm.
- 6 Incorporate ethical constructs into the delivery of care and communication with patients and their families.

Session Objectives:

- 1 • To discuss the biophysics of soluble-to-insoluble phase transformation of brain proteins and the basis of proteinopathy in neurodegeneration
- 2 • To review data from anti-A β monoclonal antibody trials for Alzheimer's disease and consider a shift in disease-modifying efforts toward protein replacement strategies.
- 3 To review the pitfalls in the prevailing gain of function (proteinopathy) model of Alzheimer's and Parkinson's diseases.

Accreditation Statement:

The University of Arizona College of Medicine - Tucson is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Arizona College of Medicine - Tucson designates this Live Activity for a maximum of 1.00 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Relevant Financial Relationships Statement(s):

University of Arizona College of Medicine - Tucson Office of Continuing Medical Education adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers or others are required to disclose all financial relationships with ineligible entities (commercial interests). The CME office reviewers have nothing to disclose. All relevant financial relationships have been mitigated prior to the commencement of the activity.

Name of individual	Individual's role in activity	Nature of Relationship(s) / Name of Ineligible Company(s)
Dedrick Jordan, MD, PhD	Activity Director	Other: Data Safety Monitoring Board-

		Acasti Pharma Paid consultant-Novo Nordisk (Any division) Paid consultant-Icon PLC - 10/30/2024
Micah Etter, MD	Planning Committee Member	Nothing to disclose - 10/30/2024
Alberto Espay, MD	Faculty	Advisor-Acadia Advisor-Acordia Advisor-Amneal Advisor-Avion Advisor-Bexion Advisor-Herantis Advisor-Kyowa Kirin Advisor-Neuroderm Advisor-Praxis Advisor-Sunovion Pharmaceuticals, Inc. Advisor-Supernus Pharmaceuticals, Inc. Consulting Fee-Acadia Consulting Fee-Acorda Consulting Fee-Amneal Consulting Fee-Bexion Consulting Fee-Herantis Consulting Fee-Kyowa Kirin Consulting Fee-Neuroderm Consulting Fee-Praxis Consulting Fee-Sunovion Pharmaceuticals, Inc. Consulting Fee-Supernus Pharmaceuticals, Inc. Grant or research support-Michael J Fox Foundation Grant or research support-NIH Royalties or Patent Beneficiary-Cambridge University Press, Royalties or Patent Beneficiary-Lippincott Williams & Wilkins Royalties or Patent Beneficiary-Springer Royalties or Patent Beneficiary-REGAIN Therapeutics - 01/09/2025



THE UNIVERSITY OF ARIZONA

College of Medicine

Tucson